{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:01:33Z","timestamp":1790690493769,"version":"4.1.0"},"reference-count":61,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Overactive bladder syndrome is highly prevalent, and increasingly so with aging. It is characterized by the presence of urinary urgency, and can be associated with incontinence, increased voiding frequency, and nocturia. Assessment needs to exclude serious medical disorders that might present with similar symptoms, and a bladder diary is an invaluable part of understanding the presentation. Initial management is conservative, comprising education, bladder training, and advice on fluid intake. Drug therapy options include antimuscarinic medications and beta-3 adrenergic receptor agonists. Persistent overactive bladder syndrome, despite initial therapy, requires a review of the patient\u2019s understanding of conservative management and compliance, and adjustment of medications. For refractory cases, specialist review and urodynamic testing should be considered; this may identify detrusor overactivity or increased filling sensation, and needs to exclude additional factors, such as stress incontinence and voiding dysfunction. Botulinum neurotoxin-A bladder injections can be used in severe overactivity, provided the patient is able and willing to do intermittent self-catheterisation, which is necessary in about 5% of treated patients. Sacral nerve stimulation and tibial nerve stimulation are other approaches. Major reconstructive surgery, such as augmentation cystoplasty, is rarely undertaken in modern practice but remains a possibility in extreme cases.<\/ns4:p>","DOI":"10.12688\/f1000research.7131.1","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T12:45:10Z","timestamp":1449578710000},"page":"1406","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Overactive bladder"],"prefix":"10.12688","volume":"4","author":[{"given":"Karen M.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"167-78","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.","volume":"21","author":"P Abrams","year":"2002","journal-title":"Neurourol Urodyn."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"622-4","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013.","volume":"33","author":"M Drake","year":"2014","journal-title":"Neurourol Urodyn."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"55-73","DOI":"10.1016\/j.mcna.2010.08.014","article-title":"Bladder pain syndrome.","volume":"95","author":"P Hanno","year":"2011","journal-title":"Med Clin North Am."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"633-7","DOI":"10.1002\/nau.20177","article-title":"Localization of the urge to void in patients with painful bladder syndrome.","volume":"24","author":"M FitzGerald","year":"2005","journal-title":"Neurourol Urodyn."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"11-5","DOI":"10.1046\/j.1464-410X.90.s3.3.x","article-title":"The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society.","volume":"90","author":"P van Kerrebroeck","year":"2002","journal-title":"BJU Int."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1306-14","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.","volume":"50","author":"D Irwin","year":"2006","journal-title":"Eur Urol."},{"key":"ref-7","doi-asserted-by":"crossref","first-page":"327-36","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States.","volume":"20","author":"W Stewart","year":"2003","journal-title":"World J Urol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"12-23","DOI":"10.1111\/j.1464-410X.2009.08369.x","article-title":"The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS.","volume":"103","author":"C Sexton","year":"2009","journal-title":"BJU Int."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"526-32","DOI":"10.1016\/j.urology.2009.06.096","article-title":"Economic costs of overactive bladder in the United States.","volume":"75","author":"M Ganz","year":"2010","journal-title":"Urology."},{"key":"ref-10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002413","article-title":"Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study.","volume":"3","author":"N Kurita","year":"2013","journal-title":"BMJ Open."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"336-48","DOI":"10.1111\/ijcp.12301","article-title":"Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy.","volume":"68","author":"A Goren","year":"2014","journal-title":"Int J Clin Pract."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"15-43","DOI":"10.1007\/978-3-642-16499-6_2","article-title":"Animal models in overactive bladder research.","author":"B Parsons","year":"2011","journal-title":"Handb Exp Pharmacol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"653-80","DOI":"10.1152\/physrev.00030.2012","article-title":"Urothelial signaling.","volume":"93","author":"L Birder","year":"2013","journal-title":"Physiol Rev."},{"key":"ref-14","first-page":"167-254","article-title":"Neural Control","author":"L Birder","year":"2009"},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"9-16","DOI":"10.1002\/nau.22465","article-title":"Lamina propria: the functional center of the bladder?","volume":"33","author":"K Andersson","year":"2014","journal-title":"Neurourol Urodyn."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"57-67","DOI":"10.1016\/S0090-4295(97)00591-8","article-title":"A myogenic basis for the overactive bladder.","volume":"50","author":"A Brading","year":"1997","journal-title":"Urology."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"401-3","DOI":"10.1016\/S0140-6736(01)05549-0","article-title":"Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function.","volume":"358","author":"M Drake","year":"2001","journal-title":"Lancet."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"506-15","DOI":"10.1124\/jpet.113.207340","article-title":"A functional analysis of the influence of \u03b23-adrenoceptors on the rat micturition cycle.","volume":"347","author":"P Sadananda","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"128-39","DOI":"10.1002\/nau.20837","article-title":"Neural control of the lower urinary tract: peripheral and spinal mechanisms.","volume":"29","author":"L Birder","year":"2010","journal-title":"Neurourol Urodyn."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"119-27","DOI":"10.1002\/nau.20841","article-title":"Neural control of the lower urinary and gastrointestinal tracts: supraspinal CNS mechanisms.","volume":"29","author":"M Drake","year":"2010","journal-title":"Neurourol Urodyn."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"36-52","DOI":"10.1016\/S0090-4295(97)00587-6","article-title":"A neurologic basis for the overactive bladder.","volume":"50","author":"W de Groat","year":"1997","journal-title":"Urology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"230-7","DOI":"10.1002\/nau.22295","article-title":"The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: results from OAB-POLL.","volume":"32","author":"K Coyne","year":"2013","journal-title":"Neurourol Urodyn."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"530-1","DOI":"10.1111\/j.1464-410X.2013.11019.x","article-title":"Relationship between overactive bladder (OAB) and irritable bowel syndrome (IBS): concurrent disorders with a common pathophysiology?","volume":"111","author":"D Daly","year":"2013","journal-title":"BJU Int."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"66-9","DOI":"10.1002\/nau.22277","article-title":"The association between overactive bladder and fibromyalgia syndrome: a community survey.","volume":"32","author":"J Chung","year":"2013","journal-title":"Neurourol Urodyn."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"2455-63","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline.","volume":"188","author":"E Gormley","year":"2012","journal-title":"J Urol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1130-42","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence.","volume":"62","author":"M Lucas","year":"2012","journal-title":"Eur Urol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"8-13","DOI":"10.1016\/j.maturitas.2014.06.009","article-title":"You are what you eat: the impact of diet on overactive bladder and lower urinary tract symptoms.","volume":"79","author":"D Robinson","year":"2014","journal-title":"Maturitas."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"877-90","DOI":"10.1016\/j.eururo.2012.07.004","article-title":"A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis.","volume":"62","author":"J Cornu","year":"2012","journal-title":"Eur Urol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"294-300","DOI":"10.1016\/j.eururo.2014.02.057","article-title":"Developing and validating the International Consultation on Incontinence Questionnaire bladder diary.","volume":"66","author":"E Bright","year":"2014","journal-title":"Eur Urol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1612-7","DOI":"10.1111\/j.1464-410X.2010.09684.x","article-title":"Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.","volume":"107","author":"R Cartwright","year":"2011","journal-title":"BJU Int."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"696-703","DOI":"10.1111\/bju.12555","article-title":"Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms.","volume":"113","author":"C Chapple","year":"2014","journal-title":"BJU Int."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"457-64","DOI":"10.1007\/s11934-013-0358-1","article-title":"Update on behavioral and physical therapies for incontinence and overactive bladder: the role of pelvic floor muscle training.","volume":"14","author":"K Burgio","year":"2013","journal-title":"Curr Urol Rep."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"740-63","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.","volume":"54","author":"G Novara","year":"2008","journal-title":"Eur Urol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"749-60","DOI":"10.1016\/j.jamda.2013.03.008","article-title":"Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community Living Centers.","volume":"14","author":"D Moga","year":"2013","journal-title":"J Am Med Dir Assoc."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1040-60","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.","volume":"62","author":"N Buser","year":"2012","journal-title":"Eur Urol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1003-8","DOI":"10.1016\/j.juro.2013.10.046","article-title":"Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.","volume":"191","author":"P Veenboer","year":"2014","journal-title":"J Urol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2288-9-55","article-title":"A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.","volume":"9","author":"S Lee","year":"2009","journal-title":"BMC Med Res Methodol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"296-305","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder.","volume":"63","author":"C Chapple","year":"2013","journal-title":"Eur Urol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"1388-95","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder.","volume":"189","author":"V Nitti","year":"2013","journal-title":"J Urol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"666-75","DOI":"10.1093\/ageing\/afu017","article-title":"The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.","volume":"43","author":"A Wagg","year":"2014","journal-title":"Age Ageing."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2490-13-45","article-title":"Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.","volume":"13","author":"V Khullar","year":"2013","journal-title":"BMC Urol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"693-701","DOI":"10.5414\/CP201979","article-title":"Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.","volume":"52","author":"M van Gelderen","year":"2014","journal-title":"Int J Clin Pharmacol Ther."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"577-88","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).","volume":"67","author":"P Abrams","year":"2015","journal-title":"Eur Urol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"487-507","DOI":"10.1111\/j.1742-1241.2010.02611.x","article-title":"Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.","volume":"65","author":"S Kaplan","year":"2011","journal-title":"Int J Clin Pract."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"118-40","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.","volume":"64","author":"M Oelke","year":"2013","journal-title":"Eur Urol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"262-70","DOI":"10.1016\/j.eururo.2014.07.013","article-title":"Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.","volume":"67","author":"M Drake","year":"2015","journal-title":"Eur Urol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1767-74","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.","volume":"110","author":"A Wagg","year":"2012","journal-title":"BJU Int."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"495-502","DOI":"10.1002\/nau.21047","article-title":"The correlation between clinical and urodynamic diagnosis in classifying the type of urinary incontinence in women. A systematic review of the literature.","volume":"30","author":"S van Leijsen","year":"2011","journal-title":"Neurourol Urodyn."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"191-4","DOI":"10.1016\/S0022-5347(05)00067-4","article-title":"Is the bladder a reliable witness for predicting detrusor overactivity?","volume":"175","author":"H Hashim","year":"2006","journal-title":"J Urol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"2258-64","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature.","volume":"183","author":"J Anger","year":"2010","journal-title":"J Urol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2416-22","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.","volume":"184","author":"R Dmochowski","year":"2010","journal-title":"J Urol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"CD005493","DOI":"10.1002\/14651858.CD005493.pub3","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome.","author":"J Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"2148-52","DOI":"10.1016\/j.juro.2013.07.017","article-title":"Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.","volume":"190","author":"M Smits","year":"2013","journal-title":"J Urol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"242-7","DOI":"10.5489\/cuaj.2711","article-title":"Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective.","volume":"9","author":"M Hassouna","year":"2015","journal-title":"Can Urol Assoc J."},{"key":"ref-55","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22707","article-title":"Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.","author":"K Noblett","year":"2014","journal-title":"Neurourol Urodyn."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"CD004202","DOI":"10.1002\/14651858.CD004202.pub2","article-title":"Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults.","author":"G Herbison","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2490-13-61","article-title":"Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review.","volume":"13","author":"G Gaziev","year":"2013","journal-title":"BMC Urol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"51-6","DOI":"10.1016\/j.ejogrb.2015.05.014","article-title":"Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial.","volume":"191","author":"O Preyer","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1619-27","DOI":"10.1007\/s11255-015-1100-3","article-title":"Patient preferences for treating refractory overactive bladder in the UK.","volume":"47","author":"H Hashim","year":"2015","journal-title":"Int Urol Nephrol."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"322-7","DOI":"10.4103\/0970-1591.120114","article-title":"Augmentation cystoplasty: Contemporary indications, techniques and complications.","volume":"29","author":"R Veeratterapillay","year":"2013","journal-title":"Indian J Urol."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"452-8","DOI":"10.1007\/s11934-008-0078-0","article-title":"Augmentation cystoplasty: what are the indications?","volume":"9","author":"P Reyblat","year":"2008","journal-title":"Curr Urol Rep."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T05:18:31Z","timestamp":1599887911000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":61,"URL":"https:\/\/doi.org\/10.12688\/f1000research.7131.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.7681.r11457","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7681.r11460","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7681.r11458","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7681.r11460","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.7681.r11458","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.7681.r11457","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.7681.r11457, Emmanuel Chartier-Kastler, Department of Urology, Universit\u00e9 Pierre et Marie Curie, Paris, France, 08 Dec 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1#referee-response-11457","order":0,"name":"referee-response-11457","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.7681.r11458, Karl-Dietrich Sievert, Department of Urology and Andrology, Paracelsus Medical University, Salzberg, Austria, 08 Dec 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1#referee-response-11458","order":1,"name":"referee-response-11458","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.7681.r11460, George Kasyan, Department of Urology, Moscow State University of Medicine and Dentistry, Moscow, Russian Federation, 08 Dec 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-1406\/v1#referee-response-11460","order":2,"name":"referee-response-11460","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}